Oligodendroglioma

Displaying 1 - 3 of 3CSV
Lassman, A. B., Hoang-Xuan, K., Polley, M.-Y. C., Brandes, A. A., Cairncross, J. G., Kros, J. M., Ashby, L. S., Taphoorn, M. J. B., Souhami, L., Dinjens, W. N. M., Laack, N. N., Kouwenhoven, M. C. M., Fink, K. L., French, P. J., Macdonald, D. R., Lacombe, D., Won, M., Gorlia, T., Mehta, M. P., & van den Bent, M. J. (2022). Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors. Journal of Clinical Oncology, 40(23), 2539–2545. https://doi.org/10.1200/jco.21.02543
Publication Date
Tom, M. C., Milano, M. T., Chao, S. T., Soltys, S. G., Knisely, J. P. S., Sahgal, A., Nagpal, S., Lo, S. S., Jabbari, S., Wang, T. J. C., Ahluwalia, M. S., Simonson, M., Palmer, J. D., Gephart, M. H., Halasz, L. M., Garg, A. K., Chiang, V. L. S., & Chang, E. L. (2022). Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and Oncology, 170, 79–88. https://doi.org/10.1016/j.radonc.2022.03.018
Publication Date
Mohile, N. A., Messersmith, H., Gatson, N. T. N., Hottinger, A. F., Lassman, A. B., Morton, J., Ney, D., Nghiemphu, P. L., Olar, A., Olson, J., Perry, J., Portnow, J., Schiff, D., Shannon, A., Shih, H. A., Strowd, R., van den Bent, M., Ziu, M., & Blakeley, J. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology, 24(3), 358–383. https://doi.org/10.1093/neuonc/noab279
Publication Date